Personalized Neoantigen Cancer Vaccine (YGNITE/CARGONAUT)
Cancer (specific type undisclosed)
Pre-clinicalActive
Key Facts
About YGION Biomedical
YGION Biomedical is a private, pre-clinical stage biotech developing a novel class of individualized cancer vaccines. Its core technology, the YGNITE platform, integrates tumor genomics, bioinformatics, and a proprietary immune-modulating carrier (CARGONAUT) to synthesize patient-specific neoantigen vaccines designed to activate the immune system precisely against tumors. The company is well-capitalized following a €15 million Series A round in 2024 and a significant Austrian research grant, positioning it to advance its platform and pipeline toward clinical development in the competitive but high-potential field of personalized oncology.
View full company profile